201 related articles for article (PubMed ID: 31177821)
1. Clinical and Angiographic Outcomes With a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold.
Chevalier B; Abizaid A; Carrié D; Frey N; Lutz M; Weber-Albers J; Dudek D; Weng SC; Akodad M; Anderson J; Stone GW
Circ Cardiovasc Interv; 2019 Jun; 12(6):e007283. PubMed ID: 31177821
[TBL] [Abstract][Full Text] [Related]
2. 6-Month Clinical and Angiographic Outcomes of a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold: The FANTOM II Study.
Abizaid A; Carrié D; Frey N; Lutz M; Weber-Albers J; Dudek D; Chevalier B; Weng SC; Costa RA; Anderson J; Stone GW;
JACC Cardiovasc Interv; 2017 Sep; 10(18):1832-1838. PubMed ID: 28935075
[TBL] [Abstract][Full Text] [Related]
3. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.
Tenekecioglu E; Serruys PW; Onuma Y; Costa R; Chamié D; Sotomi Y; Yu TB; Abizaid A; Liew HB; Santoso T
JACC Cardiovasc Interv; 2017 Jun; 10(11):1115-1130. PubMed ID: 28527768
[TBL] [Abstract][Full Text] [Related]
4. The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis): Angiographic Results and 1-Year Clinical Outcomes.
Verheye S; Vrolix M; Kumsars I; Erglis A; Sondore D; Agostoni P; Cornelis K; Janssens L; Maeng M; Slagboom T; Amoroso G; Jensen LO; Granada JF; Stella P
JACC Cardiovasc Interv; 2017 Oct; 10(20):2029-2037. PubMed ID: 28964764
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents.
Han Y; Xu B; Fu G; Wang X; Xu K; Jin C; Tao L; Li L; Hou Y; Su X; Fang Q; Chen L; Liu H; Wang B; Yuan Z; Gao C; Zhou S; Sun Z; Zhao Y; Guan C; Stone GW;
JACC Cardiovasc Interv; 2018 Feb; 11(3):260-272. PubMed ID: 29413240
[TBL] [Abstract][Full Text] [Related]
6. Second generation, sirolimus-eluting, bioresorbable Tyrocore scaffold implantation in patients with ST-segment elevation myocardial infarction: Baseline OCT and 30-day clinical outcomes - A FANTOM STEMI pilot study.
Koltowski L; Tomaniak M; Ochijewicz D; Maksym J; Roleder T; Zaleska M; Proniewska K; Opolski G; Kochman J
Catheter Cardiovasc Interv; 2020 Jul; 96(1):E1-E7. PubMed ID: 31343827
[TBL] [Abstract][Full Text] [Related]
7. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
[TBL] [Abstract][Full Text] [Related]
8. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
9. Angiographic performance of a novel sirolimus-coated balloon in native coronary lesions: the FAtebenefratelli SIrolimus COated NATIVES prospective registry.
Cortese B; Pellegrini D; Latini RA; Di Palma G; Perotto A; Orrego PS
J Cardiovasc Med (Hagerstown); 2019 Jul; 20(7):471-476. PubMed ID: 30994510
[TBL] [Abstract][Full Text] [Related]
10. Drug-Coated Balloon Versus Drug-Eluting Stent for Small-Vessel Disease: The RESTORE SVD China Randomized Trial.
Tang Y; Qiao S; Su X; Chen Y; Jin Z; Chen H; Xu B; Kong X; Pang W; Liu Y; Yu Z; Li X; Li H; Zhao Y; Wang Y; Li W; Tian J; Guan C; Xu B; Gao R;
JACC Cardiovasc Interv; 2018 Dec; 11(23):2381-2392. PubMed ID: 30522667
[TBL] [Abstract][Full Text] [Related]
11. Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery.
Wu Y; Shen L; Ge L; Wang Q; Qian J; Zhang F; Yao K; Huang D; Chen Y; Ge J
Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():630-7. PubMed ID: 26864162
[TBL] [Abstract][Full Text] [Related]
12. Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial.
Teeuwen K; van der Schaaf RJ; Adriaenssens T; Koolen JJ; Smits PC; Henriques JP; Vermeersch PH; Tjon Joe Gin RM; Schölzel BE; Kelder JC; Tijssen JG; Agostoni P; Suttorp MJ
JACC Cardiovasc Interv; 2017 Jan; 10(2):133-143. PubMed ID: 28104206
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
Han Y; Jing Q; Xu B; Yang L; Liu H; Shang X; Jiang T; Li Z; Zhang H; Li H; Qiu J; Liu Y; Li Y; Chen X; Gao R;
JACC Cardiovasc Interv; 2009 Apr; 2(4):303-9. PubMed ID: 19463441
[TBL] [Abstract][Full Text] [Related]
14. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Coronary Drug-Eluting Stent Restenosis by a Sirolimus- or Paclitaxel-Coated Balloon.
Ali RM; Abdul Kader MASK; Wan Ahmad WA; Ong TK; Liew HB; Omar AF; Mahmood Zuhdi AS; Nuruddin AA; Schnorr B; Scheller B
JACC Cardiovasc Interv; 2019 Mar; 12(6):558-566. PubMed ID: 30898253
[TBL] [Abstract][Full Text] [Related]
16. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial.
Ahn JM; Park DW; Kim YH; Song H; Cho YR; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Han S; Lee SY; Lee BK; Cho JH; Yang TH; Lee NH; Yang JY; Park JS; Shin WY; Kim MH; Bae JH; Kim MK; Yoon J; Park SJ
Circ Cardiovasc Interv; 2012 Oct; 5(5):633-40. PubMed ID: 23048051
[TBL] [Abstract][Full Text] [Related]
17. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial.
Meredith IT; Worthley S; Whitbourn R; Walters DL; McClean D; Horrigan M; Popma JJ; Cutlip DE; DePaoli A; Negoita M; Fitzgerald PJ;
JACC Cardiovasc Interv; 2009 Oct; 2(10):977-85. PubMed ID: 19850258
[TBL] [Abstract][Full Text] [Related]
18. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.
Roguin A; Kandzari DE; Marcusohn E; Koolen JJ; Doros G; Massaro JM; Garcia-Garcia HM; Bennett J; Gharib EG; Cutlip DE; Waksman R
Circ Cardiovasc Interv; 2018 Oct; 11(10):e007331. PubMed ID: 30354631
[TBL] [Abstract][Full Text] [Related]
19. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
[TBL] [Abstract][Full Text] [Related]
20. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]